Candel Therapeutics, Inc. (CADL): Price and Financial Metrics
CADL Price/Volume Stats
| Current price | $8.75 | 52-week high | $14.60 |
| Prev. close | $9.96 | 52-week low | $1.06 |
| Day low | $8.25 | Volume | 4,843,900 |
| Day high | $10.00 | Avg. volume | 2,429,363 |
| 50-day MA | $5.49 | Dividend yield | N/A |
| 200-day MA | $6.10 | Market Cap | 284.17M |
CADL Stock Price Chart Interactive Chart >
Candel Therapeutics, Inc. (CADL) Company Bio
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
CADL Price Returns
| 1-mo | 111.61% |
| 3-mo | 16.05% |
| 6-mo | 42.28% |
| 1-year | 681.25% |
| 3-year | 11.61% |
| 5-year | N/A |
| YTD | 495.24% |
| 2023 | -17.88% |
| 2022 | -77.11% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...